Domainex signs Multi-Year Agreement with Dotmatics

Dotmatics, a leading provider of scientific informatics solutions and services to the life
sciences industry announces that Domainex, a small-molecule therapeutics company that provides integrated drug research services to global pharmaceutical, biotechnology and academic partners, has signed a multi-year agreement.

Domainex will leverage Dotmatics’ software to analyse and share valuable scientific data across the full range of its offerings, from protein expression through to pre-clinical candidate delivery. Specifically, Domainex will use several key bioinformatics solutions
from the Dotmatics 5.0 suite including Browser, Studies, Vortex, Studies Notebook, Register, Inventory, Cascade, Elemental and Biologics Inventory.  This state-of-the-art software will be used to provide seamless interconnectivity of biological and chemical competences, to minimise cycle timelines and providing its clients with a more efficient service.

"It is great knowing that our investment in the Dotmatics software platform will directly benefit our clients by creating a visual interface capturing data and enabling project decision making in a just-in-time manner," said Tom Mander, Domainex COO. "It brings together the innovative and high quality protein expression, hit generation and medicinal chemistry services we offer. This agreement is a natural development of our collaborative working relationships, and we are confident that our two companies will continue to work together in a very positive way for the benefit of our clients."

"It is great knowing that our software will help advance Domainex’s innovate work in COPD drug research, epigenetics research, medicinal and computational chemistry services, protein expression and cell based and biochemical assay development offerings," said Dotmatics’ Chief Executive Officer Steve Gallagher, PhD. "This agreement is a natural progression of our working relationship and we are confident that our two companies will continue on a very positive path."